Rare Disease Patients Face Years-Long Diagnostic Journey as Tech Solutions Emerge

Rare disease patients often endure years of uncertainty before receiving an accurate diagnosis, with emerging technologies now offering potential solutions to shorten this challenging journey. A 2024 study in The Lancet Global Health estimated that 300 million people worldwide are living with a rare disease, and only 5% of approximately 100,000 rare conditions have an approved treatment.

The diagnostic odyssey for rare disease patients is lengthy. One source reports the average time between symptom onset and confirmed diagnosis is 4.7 years, with 73% of patients misdiagnosed at least once. Another source cites the average as six to eight years. These delays stem partly from limited diagnostic tools for identifying genetic conditions, which account for approximately 80% of rare diseases.

The patient population is significant: an estimated 5 to 7% of the world's population has been diagnosed with a rare disease, and in the United States, 1 in 10 people live with a rare condition. Notably, half of these patients are children. Rare diseases prevent kids from being kids, as they frequently suffer from awkward situations due to poorly understood disease mechanisms, diagnosis challenges, and difficulties in managing and obtaining medications.

For some patients, the path to diagnosis follows cancer treatment. Myelodysplastic syndrome (MDS), a group of blood cancers producing abnormal blood cells, affects 4 in 100,000 people in the US annually. It is more common in males over 60, and people who have had cancer treatments face a higher risk. One patient diagnosed with MDS five years after breast cancer treatment required chemotherapy and a bone marrow transplant, noting that only 30% of siblings are donor matches for transplants.

Early-onset Parkinson's disease presents its own challenges. Only 2% of 1 million people diagnosed with Parkinson's are under age 40. One patient received his diagnosis at 29 while filming a movie, describing it as a condition he initially saw as an "old person's disease."

Technology is showing promise in addressing these challenges. Machine learning has proven effective for identifying undiagnosed and misdiagnosed patients. ML builds phenotypes with documented sentinel symptoms in electronic medical records and claims data, then finds patients with matching features and creates lists for whom diagnostic evaluation should be elevated with specific assessments like genetic testing.

Generative AI is also advancing drug development through virtual twin technology. Companies like Exactcure in France create digital twins that simulate drug effectiveness and interactions in patients based on personal characteristics such as age, gender, kidney status, genotype, and smoking status. This simulation helps patients avoid underdoses, overdoses, and drug-drug interactions.

Digital communities and care team interactions through preferred channels like text, email, chat, and phone are also helping rare disease patients find support and manage their conditions more effectively.